MX:IONS Stock Latest News

Ionis Pharmaceuticals price target lowered to $85 from $90 at Barclays

PremiumThe Fly

8d ago

Ionis Pharmaceuticals price target lowered to $84 from $87 at Raymond James

PremiumThe Fly

9d ago

Ionis Pharmaceuticals price target lowered to $104 from $110 at Morgan Stanley

PremiumThe Fly

9d ago

Ionis Pharmaceuticals price target lowered to $84 from $94 at TD Cowen

PremiumThe Fly

9d ago

PremiumThe FlyIonis Pharmaceuticals price target lowered to $54 from $61 at BMO Capital

9d ago

Ionis Pharmaceuticals price target lowered to $85 from $95 at Canaccord

The Fly

Ionis Pharmaceuticals price target lowered to $85 from $95 at Canaccord

9d ago

Ionis Pharmaceuticals price target lowered to $56 from $69 at Goldman Sachs

The Fly

Ionis Pharmaceuticals price target lowered to $56 from $69 at Goldman Sachs

9d ago

Ionis Pharmaceuticals price target lowered to $100 from $115 at H.C. Wainwright

PremiumThe Fly

9d ago

Citi sees limited immediate downside for Ionis after pelacarsen failure

PremiumThe Fly

10d ago

Ionis Buy Rating Reiterated as Analyst Sees Limited Impact from Lp(a)HORIZON Setback and Maintains $100 Price Target

PremiumRatings

10d ago

Ionis Pharmaceuticals Updates on Novartis Pelacarsen Trial Outcome

PremiumCompany Announcements

13d ago

PremiumThe FlyNovartis announces Phase 3 pelacarsen study did not meet primary endpoint

13d ago

Ionis Pharmaceuticals: Buy Rating Backed by FDA Approval of Zanvastro and Strengthened Neurology Pipeline Upside

Ratings

Ionis Pharmaceuticals: Buy Rating Backed by FDA Approval of Zanvastro and Strengthened Neurology Pipeline Upside

13d ago

Ionis Pharmaceuticals price target raised to $61 from $60 at BMO Capital

The Fly

Ionis Pharmaceuticals price target raised to $61 from $60 at BMO Capital

13d ago

Ionis Pharmaceuticals: Buy Rating Reiterated as Early Zanvastro Approval, Rare-Disease Portfolio Strength, and Valuation Support Back Unchanged $115 Price Target

PremiumRatings

13d ago

Ionis wins FDA approval for ZANVASTRO in Alexander disease

PremiumCompany Announcements

13d ago

FDA approves Ionis drug to treat Alexander disease

PremiumThe Fly

14d ago

Ultragenyx downgraded to Sector Perform from Outperform at RBC Capital

PremiumThe Fly

14d ago

RARE

PremiumRatingsIonis Pharmaceuticals: Solid Product Momentum but Balanced Risk-Reward; Hold Rating and $69 Price Target Reiterated

17d ago

Ionis: TRYNGOLZA’s Competitive Moat Supports Reiterated Buy Rating and Unchanged $115 Price Target

Ratings

Ionis: TRYNGOLZA’s Competitive Moat Supports Reiterated Buy Rating and Unchanged $115 Price Target

17d ago

Ionis, AstraZeneca ATTR-CM trial did not meet primary endpoint